Immunsuppression bei schubförmig-remittierender Multipler Sklerose

ZUSAMMENFASSUNG

Die frühzeitige, individualisierte Therapie der schubförmig-remittierenden Multiplen Sklerose (RRMS) kann die Prognose der Patienten verändern. Wird eine Eskalationstherapie notwendig, steht heute eine ganze Reihe von Therapeutika zur Auswahl. Dabei stellt sich die Frage nach der individuell besten Strategie.

ABSTRACT

Early, individualized therapy of relapsing-remitting multiple sclerosis (RRMS) can change the prognosis of patients. If escalation therapy becomes necessary, a whole range of therapeutics are available today. This raises the question of the best individual strategy.

Schlüsselwörter

Schubförmig-remittierende Multiple Sklerose - Induktionstherapie - Erhaltungstherapie - Therapieentscheidung

Key words

Relapsing remitting multiple sclerosis - induction therapy - maintenance therapy - therapeutic decision

• Literatur

• 1 Montalban X, Gold R, Thompson AJ. et al ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Eur J Neurol 2018; 25: 215-237
• 2 Brex PS, O’Riordan Ciccarelli O. et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002; 346: 158-164
• 3 Tintoré M. The Barcelona cohort. Mult Scler 2018; 24 (Suppl. 02) 57 #154
• 4 Horakova D, Boster A, Bertolotto A. et al Alemtuzumab-treated patients with relapsing-remitting MS show low rates of conversion to secondary progressive MS: 6-year follow-up of CARE-MS I and II. Mult Scler 2017; 23 (Suppl. 03) 632 #P1195
• 5 Lorscheider J, Buzzard K, Jokubaitis V. et al Defining secondary progressive multiple sclerosis. Brain 2016; 139: 2395-2405
• 6 Jeffery D, Häring D, Piani Meier D. et al Magnetic resonance imaging parameters as predictors of physical and cognitive changes over the course of 8 years in patients with relapsing forms of multiple sclerosis. Mult Scler 2018; 24 (Suppl. 02) 223-224 #P497
• 7 Brown JWL, Coles A, Horakova D. et al The effect of disease-modifying treatments on conversion to secondary progressive multiple sclerosis. Mult Scler 2017; 23 (Suppl. 03) 32 #128
• 8 KKMS, Krankheitsbezogenes Kompetenznetz Multiple Sklerose. Qualitätshandbuch MS/NMOSD. Empfehlungen zur Therapie der Multiplen Sklerose/Neuromyelitis-optica-Spektrum-Erkrankungen für Ärzte, Stand 2019 https://www.kompetenznetz-multiplesklerose.de/wp-content/uploads/2019/09/KKNMS_Qualit%C3%A4tshandbuch-MSNMOSD_2019_webfrei.pdf letzter Abruf 30.10.2019
• 9 Burt RK, Balabanov R, Burman J. et al Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA 2019; 321: 165-174
• 10 Leist TP, Weissert R. Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol 2011; 34: 28-35
• 11 Giovannoni G, Comi G, Cook S. et al A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010; 362: 416-426
• 12 Giovannoni G, Soelberg Sorensen Cook s. et al Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. Mult Scler 2019; 25: 819-827
• 13 Giovannoni G, Rammohan K, Cook S. et al Efficacy of cladribine tablets 3.5 mg/kg in high disease activity (HDA) subgroups of patients with relapsing multiple sclerosis (RMS) in the CLARITY study. AAN 2017 Poster #360
• 14 Giovannoni G, Soelberg Sorensen P, Cook S. et al Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Mult Scler 2018; 24: 1594-1604
• 15 Muraro PA, Martin R, Mancardi GL. et al Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis. Nat Rev Neurol 2017; 13: 391-405
• 16 Sanofi Genzyme. Fachinformation Lemtrada. Stand April 2019
• 17 Merck Serono. Fachinformation Mavenclad. Stand Juli 2018
• 18 EMA-Pressemitteilung vom 12. April 2019. Use of multiple sclerosis medicine Lemtrada restricted while EMA review is ongoing https://www.ema.europa.eu/documents/press-release/use-multiple-sclerosis-medicine-lemtrada-restricted-while-ema-review-ongoing_en.pdf Letzter Zugriff am 18. Oktober 2019